Can Historical Income Statement
| CANF Stock | USD 1.54 0.03 1.91% |
Historical analysis of Can Fite income statement accounts such as Interest Expense of 15.3 K, Total Revenue of 1.1 M or Gross Profit of 1.1 M can show how well Can Fite Biopharma performed in making a profits. Evaluating Can Fite income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Can Fite's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Can Fite Biopharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Can Fite Biopharma is a good buy for the upcoming year.
Can |
About Can Income Statement Analysis
Can Fite Biopharma Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Can Fite shareholders. The income statement also shows Can investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Can Fite Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Can Fite Biopharma. It is also known as Can Fite overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Can Fite's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Can Fite Biopharma current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Can Fite Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Can Fite's Gross Profit is most likely to increase significantly in the upcoming years. The Can Fite's current Selling General Administrative is estimated to increase to about 3.4 M, while Other Operating Expenses is projected to decrease to roughly 10 M.
Can Fite income statement Correlations
Click cells to compare fundamentals
Can Fite Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Can Fite income statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Depreciation And Amortization | 14K | 65K | 12.0K | 15K | 13.5K | 21.5K | |
| Interest Expense | 363K | 227K | 63K | 14K | 16.1K | 15.3K | |
| Total Revenue | 763K | 853K | 810K | 743K | 854.5K | 1.1M | |
| Gross Profit | 763K | 853K | 810K | 743K | 854.5K | 1.1M | |
| Other Operating Expenses | 14.9M | 13.7M | 10.9M | 8.9M | 10.3M | 10.0M | |
| Operating Income | (14.1M) | (12.8M) | (10.1M) | (8.2M) | (7.4M) | (7.7M) | |
| Ebit | (14.1M) | (12.8M) | (10.1M) | (8.2M) | (7.4M) | (7.7M) | |
| Research Development | 12.0M | 9.9M | 7.8M | 6.0M | 6.9M | 6.8M | |
| Ebitda | (14.1M) | (12.8M) | (10.1M) | (8.2M) | (7.4M) | (7.7M) | |
| Total Operating Expenses | 14.9M | 13.7M | 10.9M | 8.9M | 10.3M | 10.0M | |
| Income Before Tax | (14.4M) | (12.6M) | (10.2M) | (7.6M) | (6.9M) | (7.2M) | |
| Total Other Income Expense Net | (304K) | 227K | (77K) | 561K | 504.9K | 479.7K | |
| Net Income | (14.4M) | (12.6M) | (10.2M) | (7.6M) | (6.9M) | (7.2M) | |
| Income Tax Expense | 363K | (20K) | 63K | 1.0 | 1.15 | 1.09 | |
| Selling General Administrative | 3.0M | 3.8M | 3.1M | 3.0M | 3.4M | 3.4M | |
| Net Income From Continuing Ops | (14.4M) | (12.6M) | (10.2M) | (9.0M) | (10.4M) | (10.9M) | |
| Net Income Applicable To Common Shares | (12.6M) | (14.4M) | (15.2M) | (10.2M) | (11.7M) | (12.3M) | |
| Interest Income | 44K | 24K | 222K | 506K | 455.4K | 287.6K | |
| Net Interest Income | (342K) | 2K | (77K) | 726K | 653.4K | 686.1K | |
| Reconciled Depreciation | 14K | 42K | 12K | 15K | 13.5K | 15.0K |
Currently Active Assets on Macroaxis
When determining whether Can Fite Biopharma is a strong investment it is important to analyze Can Fite's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Can Fite's future performance. For an informed investment choice regarding Can Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Can Fite Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Can Fite. If investors know Can will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Can Fite listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Can Fite Biopharma is measured differently than its book value, which is the value of Can that is recorded on the company's balance sheet. Investors also form their own opinion of Can Fite's value that differs from its market value or its book value, called intrinsic value, which is Can Fite's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Can Fite's market value can be influenced by many factors that don't directly affect Can Fite's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Can Fite's value and its price as these two are different measures arrived at by different means. Investors typically determine if Can Fite is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Can Fite's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.